Nitric oxide regulates the 26 S proteasome in vascular smooth muscle cells

It is well established that nitric oxide (NO) inhibits vascular smooth muscle cell (VSMC) proliferation by modulating cell cycle proteins. The 26S proteasome is integral to protein degradation and tightly regulates cell cycle proteins. Therefore, we hypothesized that NO directly inhibits the activity of the 26S proteasome. The three enzymatic activities (chymotrypsin-like, trypsin-like and caspase-like) of the 26S proteasome were examined in VSMC. At baseline, caspase-like activity was approximately 3.5-fold greater than chymotrypsinand trypsin-like activities. The NO donor S-nitroso-N-acetylpenicillamine (SNAP) significantly inhibited all three catalytically active sites in a timeand concentrationdependent manner (P < 0.05). Caspase-like activity was inhibited to a greater degree (77.2% P < 0.05). cGMP and cAMP analogs and inhibitors had no statistically significant effect on basal or NO-mediated inhibition of proteasome activity. Dithiothreitol, a reducing agent, prevented and reversed the NO-mediated inhibition of the 26S proteasome. Nitroso-cysteine analysis following S-nitrosoglutathione exposure revealed that the 20S catalytic core of the 26S proteasome contains 10 cysteines which were S-nitrosylated by NO. Evaluation of 26S proteasome subunit protein expression revealed differential regulation of the a and b subunits in VSMC following exposure to NO. Finally, immunohistochemical analysis of subunit expression revealed distinct intracellular localization of the 26S proteasomal subunits at baseline and confirmed upregulation of distinct subunits following NO exposure. In conclusion, NO reversibly inhibits the catalytic activity of the 26S proteasome through S-nitrosylation and differentially regulates proteasomal subunit expression. This may be one mechanism by which NO exerts its effects on the cell cycle and inhibits cellular proliferation in the vasculature. Published by Elsevier Inc.

[1]  M. Kibbe,et al.  Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. , 2008, Free radical biology & medicine.

[2]  Nick D. Tsihlis,et al.  Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. , 2008, Journal of vascular surgery.

[3]  A. Goldberg,et al.  Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.

[4]  Tohru Natsume,et al.  A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes , 2005, Nature.

[5]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[6]  P. Kloetzel,et al.  Ubiquitin-Proteasome Pathway as a New Target for the Prevention of Restenosis , 2002, Circulation.

[7]  J. Sedivy,et al.  Regulation of cyclin-Cdk activity in mammalian cells , 2002, Cellular and Molecular Life Sciences CMLS.

[8]  W. Quist,et al.  Altered ubiquitin/proteasome expression in anastomotic intimal hyperplasia. , 2001, Journal of vascular surgery.

[9]  Simon C Watkins,et al.  Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. , 2001, Journal of vascular surgery.

[10]  Simon C Watkins,et al.  Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. , 2000, Journal of vascular surgery.

[11]  E. Nabel,et al.  Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. , 2000, Circulation.

[12]  S. Kaul,et al.  Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. , 2000, Journal of the American College of Cardiology.

[13]  M. Kibbe,et al.  Inducible nitric oxide synthase and vascular injury. , 1999, Cardiovascular research.

[14]  M. Broillet.  S-Nitrosylation of proteins , 1999, Cellular and Molecular Life Sciences CMLS.

[15]  P. Kloetzel,et al.  Subcellular distribution of proteasomes implicates a major location of protein degradation in the nuclear envelope–ER network in yeast , 1998, The EMBO journal.

[16]  Simon C Watkins,et al.  Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. , 1998, Journal of the American College of Surgeons.

[17]  K. Walsh,et al.  Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. , 1998, Circulation.

[18]  Wolfgang Baumeister,et al.  The Proteasome: Paradigm of a Self-Compartmentalizing Protease , 1998, Cell.

[19]  A. Hershko.  Roles of ubiquitin-mediated proteolysis in cell cycle control. , 1997, Current opinion in cell biology.

[20]  H. Nojima,et al.  Induction of the Cyclin-dependent Kinase Inhibitor p21Sdi1/Cip1/Waf1 by Nitric Oxide-generating Vasodilator in Vascular Smooth Muscle Cells* , 1997, The Journal of Biological Chemistry.

[21]  S. Moreno,et al.  Regulation of CDK/cyclin complexes during the cell cycle. , 1997, The international journal of biochemistry & cell biology.

[22]  F. Murad.  What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? , 1997, Circulation.

[23]  L. Hung,et al.  cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. , 1997, Circulation.

[24]  A. Zalewski,et al.  Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. , 1996, Circulation.

[25]  Jesse D. Roberts,et al.  Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. , 1996, Circulation research.

[26]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.

[27]  J. Loscalzo,et al.  Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. , 1995, The Journal of clinical investigation.

[28]  R. Deshaies,et al.  Make it or break it: the role of ubiquitin-dependent proteolysis in cellular regulation. , 1995, Trends in cell biology.

[29]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Stamler,et al.  Redox signaling: Nitrosylation and related target interactions of nitric oxide , 1994, Cell.

[31]  J. Kleinschmidt,et al.  Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. , 1994, The Journal of biological chemistry.

[32]  U. Garg,et al.  Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. , 1990, Biochemical and biophysical research communications.

[33]  A. Hershko,et al.  ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Hassid,et al.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[35]  A. Clowes,et al.  Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[36]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[37]  A. Hershko,et al.  Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. , 1982, The Journal of biological chemistry.